<DOC>
	<DOCNO>NCT02134639</DOCNO>
	<brief_summary>Through investigator involvement international consortium , investigator opportunity acquire new type synthetizer radiolabelling tracer . The investigator propose project develop site , radiosynthesis 68Ga-DOTATOC evaluate prospectively diagnosis neuroendocrine tumor , compare current imaging OctreoScan® . The objective project : - validate radiosynthesis 68Ga-DOTATOC site new synthetizer - clinically evaluate , prospective preliminary study , diagnostic accuracy PET-CT 68Ga-DOTATOC comparison standard image examination .</brief_summary>
	<brief_title>PET-CT Imaging Neuro-endocrine Tumors Preliminary Clinical Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Edotreotide</mesh_term>
	<criteria>Patients 18 year Patient suspect endocrine tumor accord symptomatology , biology image pathological context ( multiple endocrine neoplasia type 1 ) initial staging : include research multifocal disease locoregional metastatic extension welldifferentiated neuroendocrine tumor ( grade 1 et/ou 2 ) Search primary tumor , especially case inaugural discovery metastasis stag know recurrence Search occult recurrence suspicion recurrence ( clinical , laboratory , image doubtful ) Patient receive low range 2 month cervicothoracoabdominalpelvic CT scintigraphy OctréoScan® Patient sign informed consent Patient affiliate beneficiary regime social security Member State European community Patient another evolutive cancer disease and/or treat less 5 year Pregnant lactate woman Premenopausal woman without effective contraception ( estrogenprogestin intrauterine contraceptive device ) Patient unable give free inform consent Persons place judicial protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>